Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Axsome rapeutics

15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome

In recent days, biotech stocks have slowed their early-August sprint. But not all shares are ready to hit the showers.

Investors Business Daily

These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year

These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year

Biotech stocks are scorching right now. But the best of the best have strong gains. Those include 10 with at least 40% growth this year.

Investors Business Daily

Axsome Therapeutics (Finally) Earns Approval. Here's What's Next

Axsome Therapeutics (Finally) Earns Approval. Here's What's Next

The drug developer earned FDA approval for a new depression treatment. Now comes the hard part.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

12 Health Care Stocks Moving In Friday's Intraday Session

How These Biotech Players Could Help Treat Covid-Fueled Depression

The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.

Investors Business Daily

Axsome Therapeutics Stock Showing Market Leadership, Earns 92 RS Rating

Axsome Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Analyst Ratings for Axsome Therapeutics

Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter:

inkl

Read news from The Economist, FT, and more,
with one subscription

Axsome Therapeutics Stock Shows Rising Relative Strength, Hits 80+

Axsome Therapeutics Stock Shows Rising Relative Strength, Hits 80+

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Investors Business Daily

Where Axsome Therapeutics Stands With Analysts

Where Axsome Therapeutics Stands With Analysts

Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter:

A Preview Of Axsome Therapeutics's Earnings

A Preview Of Axsome Therapeutics's Earnings

Axsome Therapeutics (NASDAQ:AXSM) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors need to know before the announcement. Analysts estimate that Axsome Therapeutics will report an earnings per share (EPS) of $-1.00.

Axsome Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know

Axsome Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know

Axsome Therapeutics (NASDAQ:AXSM) will host a conference call at 08:00 AM ET on May 2, 2022, to discuss Q1 2022 earnings results.

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Axsome Therapeutics Stock Sees Relative Strength Rating Jump To 92

Axsome Therapeutics Stock Sees Relative Strength Rating Jump To 92

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Investors Business Daily

Axsome Therapeutics Stock Meets 80-Plus RS Rating Benchmark

Axsome Therapeutics Stock Meets 80-Plus RS Rating Benchmark

Axsome Therapeutics sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics

Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

Investor Business Daily

Amylyx Pharmaceuticals

Endo International

Axsome rapeutics

Global Blood rapeutics

Sarepta rapeutics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play